114914-42-0
Chemical Structure
Vatinoxan
Synonym(s): MK-467; L-659066
- CAS No.: 114914-42-0
- Formula:C20H26N4O4S
- Molecular Weight:418.51
IUPAC Name: N-(2-((2R,12bS)-2'-oxo-1,3,4,6,7,12b-hexahydrospiro[benzofuro[2,3-a]quinolizine-2,4'-imidazolidin]-3'-yl)ethyl)methanesulfonamide
InChIKey: GTBKISRCRQUFNL-OXJNMPFZSA-N
SMILES: CS(=O)(NCCN([C@]1(CN2)CCN3CCC4=C(OC5=CC=CC=C54)[C@]3([H])C1)C2=O)=O
Biological Activity: Vatinoxan (MK-467) is a peripherally selective α2-Adrenoceptor antagonist. Vatinoxan blocks peripheral α2-adrenoceptor-mediated vasoconstriction, bradycardia, hyperglycemia, diuresis, lens opacity, and decreased intraocular pressure, delays pupil dilation, and maintains corneal thickness. Vatinoxan, when combined with Medetomidine (HY-17034)/benzodiazepines, reduces respiratory rate and increases pulse rate, cutaneous microcirculation, tissue oxygenation, peripheral heat loss, and cardiac index, while altering gastrointestinal perfusion and mean arterial pressure, without causing death, hypotension, or hypoglycemia, and blocks vasoconstriction of chelonian resistance arteries[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vatinoxan | 99.83% | Vatinoxan (MK-467) is a peripherally selective α2-Adrenoceptor antagonist. Vatinoxan blocks peripheral α2-adrenoceptor-mediated vasoconstriction, bradycardia, hyperglycemia, diuresis, lens opacity, and decreased intraocular pressure, delays pupil dilation, and maintains corneal thickness. Vatinoxan, when combined with Medetomidine (HY-17034)/benzodiazepines, reduces respiratory rate and increases pulse rate, cutaneous microcirculation, tissue oxygenation, peripheral heat loss, and cardiac index, while altering gastrointestinal perfusion and mean arterial pressure, without causing death, hypotension, or hypoglycemia, and blocks vasoconstriction of chelonian resistance arteries. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mustikka MP, et al. Vatinoxan Prevents Medetomidine-Associated Exophthalmos and Increased Glucose Concentrations in Blood and Aqueous Humor in Rats. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2026 Jul 14.
- [2]. Bennett R. Vatinoxan: a new development in the clinical use of α2-adrenoceptor agonists in dogs, part 1[J]. Companion Animal, 2021, 26(8): 176-181.
- [3]. Lindh E, et al. Effects of vatinoxan in rats sedated with a combination of medetomidine, midazolam and fentanyl. Acta veterinaria Scandinavica. 2024 May 31;66(1):23.
- [4]. Antila H, et al. Peripheral alpha-2 antagonist vatinoxan improves dexmedetomidine-induced perivascular cerebrospinal fluid flow without affecting electroencephalogram activity in female rats. Neuropharmacology. 2026 Apr 01;287:110828.
- [5]. Lindh E, et al. Microcirculatory impact of vatinoxan and fentanyl in male Wistar rats sedated with medetomidine and midazolam. BMC veterinary research. 2026 Apr 21;22(1):326.
- [6]. Lindh E, et al. Peripheral alpha 2-adrenergic antagonist vatinoxan improves the quality of medetomidine-midazolam sedation in Wistar rats. Veterinary anaesthesia and analgesia. 2025;52(4):386-395.
- [7]. Niemann L, et al. The impact of vatinoxan on microcirculation after intramuscular co-administration with medetomidine in Beagle dogs: a blinded crossover study. Veterinary anaesthesia and analgesia. 2022 Jul;49(4):336-343.
- [8]. Kruuse AO, et al. Predominant α-adrenoceptor control of chelonian systemic resistance arteries provides a mechanistic basis for the cardiovascular effects of α-agonist sedation. American journal of physiology. Heart and circulatory physiology. 2026 Oct 01;331(4):H1242-H1251.
